SN 38 loaded biodegradable nanofiber - Cebiotex
Alternative Names: CEB-01; CEB-01 PLGA Membrane - CebiotexLatest Information Update: 13 Aug 2024
At a glance
- Originator Polytechnic University of Catalonia; The Sant Joan de Deu Hospital in Barcelona
- Developer Cebiotex
- Class Antineoplastics; Camptothecins; Indolizines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- Phase I Soft tissue sarcoma
Most Recent Events
- 29 Jul 2024 Phase-II clinical trials in Pancreatic cancer (Late-stage disease) in Spain (unspecified route, Controlled release) (NCT06538857)
- 31 May 2024 Efficacy, adverse events and pharmacokinetics data from a phase-I trial in Soft tissue sarcoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 14 Dec 2023 Phase-I development in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in Spain (NCT04619056)